Azenta, Inc. - Common Stock (NQ:AZTA)

38.75 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Azenta, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Azenta (NASDAQ:AZTA) Misses Q2 Sales Targets

August 05, 2025

Life sciences company Azenta (NASDAQ:AZTA) fell short of the market’s revenue expectations in Q2 CY2025, with sales flat year on year at $143.9 million. Its non-GAAP profit of $0.14 per share was in...

Via StockStory

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

Azenta (AZTA) Q2 Earnings Report Preview: What To Look For

August 03, 2025

Life sciences company Azenta (NASDAQ:AZTA) will be reporting results this Tuesday before the bell. Here’s what to look for.

Via StockStory

Fortrea, Azenta, Bio-Techne, 10x Genomics, and Amphastar Pharmaceuticals Stocks Trade Up, What You Need To Know

July 23, 2025

A number of stocks jumped in the afternoon session after a new trade agreement between the United States and Japan spurred a broad market rally.

Via StockStory

Topics Stocks World Trade

Stocks making big moves yesterday: Vital Farms, Robinhood, Simmons First National, Medpace, and Azenta

July 23, 2025

Check out the companies making headlines yesterday:

Via StockStory

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

Insights Ahead: Azenta's Quarterly Earnings ↗

May 06, 2025

Via Benzinga

Why Azenta (AZTA) Stock Is Up Today

July 22, 2025

Shares of life sciences company Azenta (NASDAQ:AZTA) jumped 5.7% in the afternoon session after the investment firm Stephens initiated coverage on the life sciences company.

Via StockStory

Topics Artificial Intelligence Lawsuit

Repligen, Bruker, Fortrea, Azenta, and Biogen Stocks Trade Down, What You Need To Know

July 18, 2025

A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like...

Via StockStory

Topics Lawsuit

Winners And Losers Of Q1: Azenta (NASDAQ:AZTA) Vs The Rest Of The Drug Development Inputs & Services Stocks

July 17, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Azenta (NASDAQ:AZTA) and the best and worst...

Via StockStory

Q1 Earnings Outperformers: Azenta (NASDAQ:AZTA) And The Rest Of The Drug Development Inputs & Services Stocks

July 16, 2025

Let’s dig into the relative performance of Azenta (NASDAQ:AZTA) and its peers as we unravel the now-completed Q1 drug development inputs & services earnings season.

Via StockStory

3 Low-Volatility Stocks in the Doghouse

July 03, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

3 Healthcare Stocks Skating on Thin Ice

June 30, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of...

Via StockStory

Topics Stocks

3 of Wall Street’s Favorite Stocks Facing Headwinds

June 13, 2025

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...

Via StockStory

3 Small-Cap Stocks in Hot Water

June 04, 2025

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...

Via StockStory

Waters Corporation, Avantor, Azenta, Bio-Techne, and Elanco Stocks Trade Up, What You Need To Know

May 12, 2025

A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides...

Via StockStory

Topics Government Stocks World Trade

AZTA Q1 Earnings Call: Revenue Tops Expectations, Margin Progress Amid Macro Headwinds

May 09, 2025

Life sciences company Azenta (NASDAQ:AZTA) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 5.2% year on year to $143.4 million. Its non-GAAP profit of $0.05 per...

Via StockStory

Topics World Trade

Azenta (NASDAQ:AZTA) Beats Q1 Sales Targets

May 07, 2025

Via StockStory

Azenta (AZTA) Q1 Earnings Report Preview: What To Look For

May 06, 2025

Life sciences company Azenta (NASDAQ:AZTA) will be reporting results tomorrow morning. Here’s what investors should know.

Via StockStory

2 Cash-Heavy Stocks Worth Your Attention and 1 to Approach with Caution

April 29, 2025

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining...

Via StockStory

3 Cash-Producing Stocks Facing Headwinds

April 21, 2025

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Via StockStory

3 of Wall Street’s Favorite Stocks in the Doghouse

April 10, 2025

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...

Via StockStory

3 Reasons AZTA is Risky and 1 Stock to Buy Instead

March 27, 2025

Shareholders of Azenta would probably like to forget the past six months even happened. The stock dropped 23.7% and now trades at $37.66. This might have investors contemplating their next move.

Via StockStory

Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks

March 26, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how IQVIA (NYSE:IQV) and the rest...

Via StockStory

Unpacking Q4 Earnings: West Pharmaceutical Services (NYSE:WST) In The Context Of Other Drug Development Inputs & Services Stocks

March 25, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at West Pharmaceutical Services (NYSE:WST) and its peers.

Via StockStory

Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers

March 21, 2025

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Medpace (NASDAQ:MEDP) and its peers.

Via StockStory

Drug Development Inputs & Services Stocks Q4 Results: Benchmarking Fortrea (NASDAQ:FTRE)

March 18, 2025

Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug development inputs & services earnings season.

Via StockStory

Unpacking Q4 Earnings: UFP Technologies (NASDAQ:UFPT) In The Context Of Other Drug Development Inputs & Services Stocks

March 13, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at drug development inputs & services stocks,...

Via StockStory

Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks

March 12, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Azenta (NASDAQ:AZTA) and its peers.

Via StockStory

1 Small-Cap Stock with Exciting Potential and 2 to Brush Off

March 11, 2025

Via StockStory

Topics Supply Chain

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.